Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ARVN

Arvinas Inc

May 08 • 04:00PM ET

32.37

Dollar change -1.96
Percentage change -5.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF IWM VBK IWO IBB SCHA VHT VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.93	Insider Own	13.61%	Shs Outstand	68.00M	Perf Week	-0.34%
Market Cap	2.21B	Forward P/E	-	EPS next Y	-4.88	Insider Trans	-0.11%	Shs Float	59.01M	Perf Month	-14.99%
Income	-354.80M	PEG	-	EPS next Q	-1.31	Inst Own	89.54%	Short Float	15.15%	Perf Quarter	-31.82%
Sales	71.30M	P/S	31.01	EPS this Y	29.79%	Inst Trans	-1.07%	Short Ratio	11.86	Perf Half Y	91.20%
Book/sh	8.93	P/B	3.63	EPS next Y	-5.01%	ROA	-29.71%	Short Interest	8.94M	Perf Year	31.21%
Cash/sh	17.20	P/C	1.88	EPS next 5Y	-	ROE	-63.32%	52W Range	13.57 - 53.08	Perf YTD	-21.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.62%	ROI	-58.09%	52W High	-39.02%	Beta	2.00
Dividend TTM	-	Quick Ratio	4.94	Sales past 5Y	80.30%	Gross Margin	90.60%	52W Low	138.54%	ATR (14)	1.79
Dividend Ex-Date	-	Current Ratio	4.94	EPS Y/Y TTM	-22.31%	Oper. Margin	-511.46%	RSI (14)	38.29	Volatility	5.79% 5.07%
Employees	445	Debt/Eq	0.00	Sales Y/Y TTM	-46.03%	Profit Margin	-497.62%	Recom	1.25	Target Price	68.94
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	37.01%	Payout	-	Rel Volume	0.91	Prev Close	34.33
Sales Surprise	-23.20%	EPS Surprise	31.68%	Sales Q/Q	-22.15%	Earnings	May 07 BMO	Avg Volume	753.77K	Price	32.37
SMA20	-3.99%	SMA50	-17.86%	SMA200	2.90%	Trades		Volume	688,281	Change	-5.71%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-24	Reiterated	Oppenheimer	Outperform	$95 → $80
Feb-14-24	Downgrade	Citigroup	Buy → Neutral	$36 → $55
Feb-01-24	Initiated	Goldman	Buy	$70
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $63
Dec-06-23	Upgrade	Jefferies	Hold → Buy	$40
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $49
Sep-09-22	Initiated	Barclays	Overweight	$90
Jun-21-22	Initiated	Jefferies	Hold	$42
May-09-22	Downgrade	Wedbush	Outperform → Neutral
Apr-28-22	Initiated	Credit Suisse	Outperform	$104
Apr-06-22	Initiated	Morgan Stanley	Equal-Weight	$65
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$125
Feb-10-22	Initiated	Wells Fargo	Overweight	$98
Jan-19-22	Initiated	Goldman	Buy	$157
Dec-07-21	Initiated	Cowen	Outperform
Oct-14-21	Initiated	SVB Leerink	Outperform	$115

Show Previous Ratings

Today 08:36AM	Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating (MT Newswires) -5.71%
May-07-24 01:54PM	ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.42%
10:27AM	Arvinas Shares Up After Q1 Net Loss Narrows (MT Newswires)
08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
10:00AM	Loading…
May-02-24 10:00AM	Why Earnings Season Could Be Great for Arvinas (ARVN) (Zacks)
07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
May-01-24 12:00PM	Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-26-24 10:00AM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-24 04:30PM	Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer (GlobeNewswire)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
12:25PM	Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024 (Associated Press Finance)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
08:06AM	Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader (FierceBiotech.com)
07:40AM	Loading…
07:40AM	UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion (Reuters)
07:17AM	Novartis licenses Arvinas' cancer drug for up to $1 billion (Reuters)
07:00AM	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer (GlobeNewswire)
Apr-09-24 08:48AM	Is Arvinas (ARVN) Stock a Solid Choice Right Now? (Zacks)
Mar-18-24 04:40PM	Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -5.02%
Mar-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-24 08:30AM	Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? (Zacks)
Feb-27-24 08:30AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-24 09:55AM	Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High? (Zacks)
Feb-21-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now? (Zacks) -5.73%
Feb-20-24 04:05PM	Arvinas Announces Chief Financial Officer Transition (GlobeNewswire)
07:00AM	Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease (GlobeNewswire)
Feb-14-24 08:00AM	Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer (GlobeNewswire)
Feb-08-24 08:26AM	Goldman Sachs Predicts at Least 45% Rally for These 2 Strong Buy Stocks Heres Why They Have Solid Upside (TipRanks)
09:55AM	Loading…
Feb-06-24 09:55AM	Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet (Zacks) +5.85%
06:45AM	Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
Feb-02-24 02:59AM	Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Feb-01-24 04:30PM	Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference (GlobeNewswire) +10.00%
Jan-17-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock (Zacks)
Jan-16-24 05:01PM	Arvinas Appoints Jared Freedberg as General Counsel (GlobeNewswire)
Jan-01-24 09:55AM	Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:40AM	Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-27-23 05:03AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024 (TipRanks)
Dec-25-23 09:55AM	Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-15-23 09:40AM	Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-05-23 10:52PM	Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program (GlobeNewswire)
01:33PM	Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE ) and Plans to Expand Vepdegestrant Development Program (GlobeNewswire)
Dec-01-23 09:55AM	Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect? (Zacks) +7.42%
Nov-28-23 05:05PM	Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 07:00AM	Arvinas Announces Oversubscribed $350 Million Private Placement (GlobeNewswire) +10.24%
Nov-15-23 09:55AM	Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know (Zacks)
Nov-13-23 09:55AM	Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +10.67%
Nov-07-23 08:02AM	Arvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate Update (GuruFocus.com) +5.08%
07:00AM	Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 07:39AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength? (Zacks) +6.90%
Oct-22-23 07:00AM	Potential of Arvinas' PROTAC AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC (GlobeNewswire)
Oct-18-23 07:00AM	Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day (GlobeNewswire) -6.56%
Oct-15-23 06:07PM	Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
06:05PM	Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Sep-01-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 10:54AM	Oppenheimer Says These 2 Beaten-Down Stocks Could Double Your Money Heres Why They Could Rebound (TipRanks)
Aug-10-23 07:06AM	Wall Street Analysts Trim Price Targets for These 10 Stocks (Insider Monkey)
06:02AM	Growth Investors: Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 13% (Simply Wall St.)
Aug-08-23 09:05AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 04:30PM	Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer (GlobeNewswire) +10.26%
Jul-06-23 09:00AM	Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination (GlobeNewswire) -5.94%
Jun-28-23 08:29PM	Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 Strong Buy Names With Solid Upside Potential (TipRanks)
Jun-17-23 08:57AM	Loss-making Arvinas (NASDAQ:ARVN) has seen earnings and shareholder returns follow the same downward trajectory over past -24% (Simply Wall St.)
Jun-15-23 04:30PM	Arvinas Announces Changes to its Board of Directors (GlobeNewswire)
Jun-13-23 04:51AM	Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last? (Zacks) +9.21%
Jun-08-23 01:05PM	Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations (Benzinga)
07:00AM	Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations (GlobeNewswire)
Jun-05-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-23 07:00AM	Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress (GlobeNewswire)
May-07-23 08:04AM	New Forecasts: Here's What Analysts Think The Future Holds For Arvinas, Inc. (NASDAQ:ARVN) (Simply Wall St.)
May-05-23 08:35AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.61%
07:00AM	Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 07:00AM	Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 01:00PM	Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial (PR Newswire) -7.69%
Apr-21-23 04:00PM	Arvinas to Present at Stifel Targeted Oncology Day (GlobeNewswire) +5.51%
Apr-17-23 08:01AM	Arvinas, Inc. (NASDAQ:ARVN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
Apr-14-23 03:32AM	Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Apr-03-23 07:00AM	Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership (GlobeNewswire)
Feb-27-23 04:00PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 05:10AM	A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN) (Simply Wall St.)
05:10AM	Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Feb-23-23 08:45AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-06-23 04:30PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-11-23 08:35AM	Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock? (Zacks)
Jan-04-23 07:00AM	Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.22%
Jan-03-23 07:11AM	Investors in Arvinas (NASDAQ:ARVN) from a year ago are still down 57%, even after 5.4% gain this past week (Simply Wall St.)
Dec-16-22 09:00AM	Arvinas Announces Changes to its Board of Directors (GlobeNewswire)
Nov-25-22 04:04AM	Analysts Say These 2 Strong Buy Stocks Are Their Top Picks for 2023 (TipRanks)
Nov-22-22 11:20AM	Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting (Benzinga) -5.52%
07:12AM	Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) (GlobeNewswire)
Nov-08-22 08:15AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-22 04:00PM	Arvinas to Present at Upcoming Conferences (GlobeNewswire)
08:32AM	Why Arvinas (ARVN) Might Surprise This Earnings Season (Zacks)

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Houston John G	President and CEO	Feb 23 '24	Sale	47.05	5,196	244,472	1,036,681	Feb 27 06:35 PM
Cassidy Sean A	Chief Financial Officer	Feb 23 '24	Sale	47.05	1,702	80,079	181,916	Feb 27 06:34 PM
Taylor Ian	Chief Scientific Officer	Feb 23 '24	Sale	47.05	1,701	80,032	147,522	Feb 27 06:33 PM
Peck Ronald	Chief Medical Officer	Feb 23 '24	Sale	47.05	1,699	79,938	67,516	Feb 27 06:34 PM
Taylor Ian	Chief Scientific Officer	Jan 04 '24	Option Exercise	16.00	8,252	132,032	109,973	Jan 08 04:39 PM
Peck Ronald	Chief Medical Officer	Aug 11 '23	Sale	24.39	1,324	32,289	29,965	Aug 14 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience